Table 3
Population Guideline Adherence and Impact of Electronic Reminders on Medication Laboratory Monitoring
| Medication–Lab Reminder | Arm | # Visits | # Visits with Lab Overdue (%) | # Lab Ordered when Overdue (%) | Odds Ratio (Adjusted) | p-Value |
| NSAID–Cr | C | 9307 | 428 (4.6%) | 136 (31.8%) | 1.24 (0.71–2.15) | 0.457 |
| I | 8487 | 442 (5.2%) | 150 (33.9%) | |||
| ARB–Cr | C | 832 | 27 (3.2%) | 17 (63.0%) | 0.24 (0.04–1.34) | 0.104 |
| I | 751 | 31 (4.1%) | 17 (54.8%) | |||
| Metformin–Cr | C | 781 | 16 (2.1%) | 6 (37.5%) | 0.53 (0.05–5.34) | 0.594 |
| I | 856 | 20 (2.3%) | 7 (35.0%) | |||
| K Supplement–K | C | 751 | 9 (1.2%) | 5 (55.5%) | 0.91 (0.03–24.44) | 0.956 |
| I | 579 | 12 (2.1%) | 7 (58.3%) | |||
| K Sparing Diuretic–K | C | 875 | 28 (3.2%) | 17 (60.7%) | 0.82 (0.12–5.60) | 0.836 |
| I | 761 | 19 (2.5%) | 13 (68.4%) | |||
| Thiazide Diuretic–K | C | 2508 | 89 (3.5%) | 46 (51.7%) | 1.30 (0.63–2.67) | 0.473 |
| I | 1997 | 62 (3.1%) | 40 (64.5%) | |||
| ACE Inhibitor–K | C | 2790 | 80 (2.9%) | 40 (50.0%) | 1.00 (0.43–2.30) | 0.993 |
| I | 2279 | 119 (5.2%) | 57 (47.9%) | |||
| Statin–ALT | C | 10935 | 674 (6.2%) | 358 (53.1%) | 0.89 (0.43–1.81) | 0.740 |
| I | 9441 | 613 (6.5%) | 291 (47.5%) | |||
| Thyroxine–TSH | C | 1233 | 44 (3.6%) | 25 (56.8%) | 1.19 (0.40–3.53) | 0.747 |
| I | 897 | 38 (4.2%) | 22 (57.9%) | |||
| Therapeutic Level* | C | 755 | 26 (3.4%) | 4 (15.4%) | 0.55 (0.03–8.94) | 0.677 |
| I | 514 | 16 (3.1%) | 2 (12.5%) |
-
↵* This represents the aggregated reminders for Therapeutic monitoring the following medications: carbamazapine, cyclosporine, Phenobarbital, phenytoin, Proc-NAPA, valproate.
-
C = Control; I = Intervention. Please refer to Table 1 for medication abbreviations.
